Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

3.8K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
3.8K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

214
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
214
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

3.5K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
3.5K
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

2.4K
Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
2.4K
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

3.2K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
3.2K
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

2.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.5K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Acute injury characteristics predict chronic neuropathic pain development after spinal cord injury.

Frontiers in neurology·2026
Same author

Insurance-based disparities in traumatic brain injury length of stay and discharge dispositions: A retrospective cohort analysis of the national trauma data bank.

Injury·2026
Same author

Traumatic Brain Injury in Female Intimate Partner Violence Survivors: Incidence, Sociodemographic Disparities, and Clinical Outcomes.

Journal of interpersonal violence·2026
Same author

Does insurance type influence patient-reported satisfaction at 60 months following surgery for cervical myelopathy? A Spine CORe™ analysis of QOD data.

Neurosurgical focus·2026
Same author

Hospital Medicaid payer mix associated with inpatient mortality following traumatic brain injury.

The journal of trauma and acute care surgery·2026
Same author

Quality of Life and Function from Initial Injury to Follow-up in the First Year after Traumatic Spinal Cord Injury.

Journal of neurotrauma·2026
Same journal

Designing Care Beyond the Hospital: Revealing Hidden Care Demands in Hospital-At-Home Services.

Inquiry : a journal of medical care organization, provision and financing·2026
Same journal

Fundamental Values in Nursing Care: The Person's Perspective.

Inquiry : a journal of medical care organization, provision and financing·2026
Same journal

Network Analysis of Healthcare Worker Burnout: Organizational Factors Show Highest Centrality.

Inquiry : a journal of medical care organization, provision and financing·2026
Same journal

Corrigendum to: "A Systematic Review on the Effectiveness of the Cure Violence Approach".

Inquiry : a journal of medical care organization, provision and financing·2026
Same journal

Nurse Influencers: The Digital Performance of Care, Professional Identity, and the Commodification of Empathy-An Integrative Narrative Review.

Inquiry : a journal of medical care organization, provision and financing·2026
Same journal

Digital Access and Primary Care Use in Chronic Disease Management: Preliminary Evidence From Three Caribbean Cities in Colombia.

Inquiry : a journal of medical care organization, provision and financing·2026
関連記事をすべて見る

関連する実験動画

Updated: Jan 8, 2026

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT
11:34

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

9.2K

契約薬局を通じた340B資金の流れのマッピング

Anthony M DiGiorgio1,2, Parisa Jahangirizadeh3, Deborah Williams4

  • 1The University of California, San Francisco, CA, USA.

Inquiry : a journal of medical care organization, provision and financing
|December 24, 2025
PubMed
まとめ
この要約は機械生成です。

340B医薬品価格設定プログラム

キーワード:
340B医療政策契約薬局対象エンティティ医薬品価格設定薬局給付管理者第三者管理者

さらに関連する動画

Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS
09:58

Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS

Published on: April 18, 2018

9.4K
Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
16:19

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

13.2K

関連する実験動画

Last Updated: Jan 8, 2026

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT
11:34

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

9.2K
Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS
09:58

Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry LCM-LC/MS

Published on: April 18, 2018

9.4K
Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
16:19

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

13.2K

科学分野:

  • 医療経済学; 医薬品政策; ヘルスケア管理

背景:

  • 340B医薬品価格設定プログラム（340B）は、セーフティネット提供者の医薬品コストを削減することを目的としています。
  • プログラムの拡大と契約薬局の使用は、その現在の影響と機能についての懸念を引き起こしています。

研究 の 目的:

  • 現代の340Bプログラム内の資金の流れを分析すること。
  • 契約薬局とPBMに焦点を当て、利益の流用とプログラムの本来の意図との乖離を特定すること。

主な方法:

  • 340Bエコシステム内の財務取引の詳細なマッピング。
  • 対象エンティティ、契約薬局、TPA、PBMが関与する利益インセンティブと資金の流れの分析。

主要な成果:

  • 対象エンティティは340B医薬品から相当な利益を得ており、低所得者層への再投資を義務付けるものはない。;契約薬局とTPAは、流用と二重割引の複雑さとリスクを高める。;垂直統合されたPBM薬局チェーンは相当な収益を占める。

結論:

  • 現在の340Bプログラムは、利益インセンティブと患者ケア目標との間に乖離を示しています。
  • 340Bプログラムを本来の受益者である低所得者および脆弱な患者に焦点を戻すためには、立法および行政改革が必要です。